We are thrilled to share that we conducted the successful execution of the Paediatric Demonstration Study (PDS) qualitative training in Addis Ababa, Ethiopia, from March 11th to 14th, 2025.
About the Paediatric Demonstration Study
The PDS is part of the IMPAACT4TB evidence-generative approach on a child-friendly formulation of rifapentine. This is a dispersible raspberry mint-flavored formulation that simplifies the treatment process for children and caregivers designed for a three-month, once-weekly regimen (3HP). Traditional TB preventive treatment often involve lengthy regimens, with many large and bitter pills, that can be challenging for children to complete, therefore this child-friendly formulation has the potential to enhance adherence, making it more suitable, sustainable and person-centered.
Paediatric Demonstration Study – Qualitative Training in Addis Ababa, Ethiopia
The PDS qualitative training in Ethiopia brought together a dedicated team of professionals from the Aurum Institute and KNCV Tuberculosis Foundation, and aimed at equipping participants with essential knowledge and skills for conducting qualitative research as part of the study.
The training included interactive sessions tailored to support interviewers, transcribers, and translators, ensuring they are well-prepared to contribute effectively to the study. Participants received a comprehensive introduction to the new child-friendly dispersible 3HP formulation for Tuberculosis Preventive Therapy (TPT) and the study’s key objectives. Through detailed discussions on protocols and Standard Operating Procedures (SOPs), the participants learned crucial techniques, including:
- Obtaining informed consent from caregivers, healthcare workers, and policymakers.
- Conducting qualitative interviews with accuracy and sensitivity.
- Managing audio recording, transcription, and translation of data.
To reinforce these skills, the training incorporated interactive role-playing sessions, allowing participants to practice consent procedures and interview techniques in real-world scenarios. This hands-on approach fostered a dynamic and engaging learning environment, encouraging active participation and collaboration through group discussions and reflective exercises.
The training was supported by a variety of materials, including:
- Study documents (protocols, interview guides, consent forms).
- Tape recorders for role-playing and interview practice.
- Blister packs of Rifapentine and INH dispersible tablets for demonstration purposes.
This qualitative training of the Paediatric Demonstration Study in Ethiopia marks a significant milestone in advancing the evidence generation on the child-friendly 3HP formulation. This reinforces our commitment to high-quality research and impactful health interventions. We extend our gratitude to all the participants and facilitators for their dedication and enthusiasm in making this session a success!
The IMPAACT4TB Consortium
The IMPAACT4TB Consortium is funded by Unitaid and led by the Aurum Institute. The consortium is comprised of the Clinton Health Access Initiative (CHAI), Johns Hopkins University, KNCV Tuberculosis Foundation and the Treatment Action Group (TAG).
The IMPAACT4TB Consortium’s efforts to scale up access to these shorter, more palatable regimens represent a vital step toward ending TB in children and adolescents.
Together we can end TB!